Olanzapine (Zyprexa) Withdrawal: Severe Risks, Tapering Protocol, and Medical Supervision

Critical Warning: Never Stop Olanzapine Abruptly

Olanzapine (a second-generation antipsychotic) discontinuation syndrome can be severe, life-threatening, or fatal, especially after long-term or high-dose use.

Withdrawal Symptoms (Onset: Days to Weeks After Last Dose)

• Severe anxiety, agitation, insomnia
• Nausea, vomiting, diarrhea
• Dizziness, orthostatic hypotension
• Rebound psychosis (hallucinations, delusions, disorganization)
• Confusion, cognitive impairment
• Seizures (lowered threshold)
• Autonomic instability (tachycardia, sweating, fever)
• Movement disorders (akathisia, dystonia)

Mandatory Tapering Protocol

• Reduce by ≤10–25% of current dose every 2–4 weeks.
• Slower at lower doses (last 5–10 mg most difficult).
• Monitor weekly for emergence of symptoms.
• Pause or increase dose if withdrawal emerges.
• Total taper: months to >1 year.

Clinical Supervision Required

• Some patients need inpatient taper (history of severe withdrawal, high dose, comorbid substance use).
• Benzodiazepines short-term for anxiety/insomnia during taper.
• Switching to long-acting injectable (LAI) may smooth transition.

Patient and family education is essential. Never self-discontinue. Always partner with your prescriber.